The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.

This video features Dr. Eric Simpson's presentation on the importance of achieving disease control in adults with moderate-to-severe AD. Dr. Simpson discusses how adult patients and HCPs talk about disease control and the tools available to help define it. He also explores the roles of IL-4 and IL-13 in the pathophysiology of AD, including how both cytokines promote inflammation and, in turn, contribute to the cumulative burden of the disease. The video concludes with a brief panel discussion.

Drs Stephanie Christenson and Jean Bourbeau explore the role of type 2 inflammation in Chronic Obstructive Pulmonary Disease (COPD).

Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.

Drs. Elmariah, Kim, and Metz explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.
Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.
Explore how type 2 inflammation drives the production of FeNO in severe asthma
Explore how type 2 inflammation drives the production of IgE in severe asthma
Explore how type 2 inflammation drives the production of eosinophils in severe asthma.
Professor Sarina Elmariah describes how IL-4 and IL-13, key drivers of type 2 inflammation, uniquely contribute to manifestations of prurigo nodularis beyond itch.
Professor Sarina Elmariah highlights the multifaceted role of IL-4 and IL-13 in driving dermal fibrosis in prurigo nodularis, which leads to persistent scarring and dyspigmentation that significantly contribute to patients' embarrassment, anxiety, depression, and self-esteem.

In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to the systemic inflammation seen in patients with moderate-to-severe AD.